293 related articles for article (PubMed ID: 25170205)
1. Selection criteria in resectable pancreatic cancer: a biological and morphological approach.
Tamburrino D; Partelli S; Crippa S; Manzoni A; Maurizi A; Falconi M
World J Gastroenterol; 2014 Aug; 20(32):11210-5. PubMed ID: 25170205
[TBL] [Abstract][Full Text] [Related]
2. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
[TBL] [Abstract][Full Text] [Related]
3. New challenges in perioperative management of pancreatic cancer.
Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
[TBL] [Abstract][Full Text] [Related]
4. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
5. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
6. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
7. Significance of aggressive surgery for an invasive carcinoma derived from an intraductal papillary mucinous neoplasm diagnosed preoperatively as borderline resectable.
Aimoto T; Mizutani S; Kawano Y; Suzuki H; Uchida E
J Nippon Med Sch; 2013; 80(5):371-7. PubMed ID: 24189355
[TBL] [Abstract][Full Text] [Related]
8. Prediction of survival after left-sided pancreatic resection for adenocarcinoma: Introduction of a new prognostic score.
Gwiasda J; Qu Z; Schrem H; Oldhafer F; Winny M; Klempnauer J; Grannas G; Kaltenborn A
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):569-575. PubMed ID: 31279680
[TBL] [Abstract][Full Text] [Related]
9. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
[TBL] [Abstract][Full Text] [Related]
11. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
12. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
Xu B; Ding WX; Jin DY; Wang DS; Lou WH
World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
[TBL] [Abstract][Full Text] [Related]
13. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
14. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?
Marchegiani G; Andrianello S; Perri G; Secchettin E; Maggino L; Malleo G; Bassi C; Salvia R
HPB (Oxford); 2018 May; 20(5):411-417. PubMed ID: 29191689
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer.
Kim HW; Lee JC; Paik KH; Kang J; Kim YH; Yoon YS; Han HS; Kim J; Hwang JH
Surgery; 2017 Jun; 161(6):1579-1587. PubMed ID: 28237643
[TBL] [Abstract][Full Text] [Related]
16. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
[TBL] [Abstract][Full Text] [Related]
17. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
[TBL] [Abstract][Full Text] [Related]
18. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
[TBL] [Abstract][Full Text] [Related]
19. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]